These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26840480)

  • 41. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
    Ciriacks K; Coly G; Krishnaswami S; Patel SB; Kidambi S
    Metab Syndr Relat Disord; 2015 Mar; 13(2):84-90. PubMed ID: 25490061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
    Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
    J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Clin Biochem; 2011 Jun; 44(8-9):627-34. PubMed ID: 21349260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.
    Chan SY; Mancini GB; Ignaszewski A; Frohlich J
    BMC Clin Pharmacol; 2008 Oct; 8():10. PubMed ID: 18957124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.
    Ravandi A; Boekholdt SM; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Tsimikas S
    J Lipid Res; 2011 Oct; 52(10):1829-36. PubMed ID: 21821825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
    Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
    Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study.
    Yao T; Lu W; Ke J; Zhang H; Zhao X; Song B; Liu T; Ke Q; Liu C
    Front Endocrinol (Lausanne); 2022; 13():865863. PubMed ID: 35573992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease.
    Takamiya Y; Miura S; Kawamura A; Tanigawa H; Zhang B; Iwata A; Nishikawa H; Matsuo K; Shirai K; Saku K
    Coron Artery Dis; 2009 Jun; 20(4):288-94. PubMed ID: 19440067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction of myocardial ischemia with simvastatin in addition to conventional treatment in patients with chronic coronary artery disease.
    Verri V; Cunha AB; Tessarolo LE; Carneiro RC; Romêo Filho LJ
    Rev Port Cardiol; 2004 Sep; 23(9):1089-105. PubMed ID: 15587571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial.
    Nishikido T; Oyama J; Keida T; Ohira H; Node K
    J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
    Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
    Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
    J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Positive correlation between in vivo oxidized LDL and LDL immune complexes.
    Bing H; Wang J; Zhang C; Cai H
    Clin Biochem; 2004 Jan; 37(1):72-5. PubMed ID: 14675566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.